CSL:
The current market price is 140.93, with no available percentage change from the previous price.
Support and Resistance Levels
The pivot point is 140.93, with three support levels at 140.93 and three resistance levels at 140.93.
Indicators
The RSI is currently at 100, remaining unchanged in the history, indicating overbought conditions. The ATR is at 0, signaling low volatility. The Parabolic SAR is at 140.93, unchanged, suggesting a continued trend. The various moving averages (SMA and EMA) are all at 140.93, indicating a flat trend.
Market Sentiment
Given the price is at the pivot point of 140.93, the market may remain neutral, but the overbought RSI suggests caution.
CSL Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
CSL Limited, listed on the CXA exchange under the symbol CSL, is a global biotechnology leader headquartered in Australia. Established in 1916, CSL has a rich history of innovation, primarily focusing on the development of biotherapies for diverse medical conditions. The company initially started as a government-owned entity, primarily involved in the production of blood plasma products. Over the decades, CSL transformed into a publicly traded company and has expanded its operations globally, operating in over 35 countries with a workforce exceeding 30,000 dedicated employees.
Market Position
CSL Limited holds a prominent position in the biotechnology industry, ranking among the top global biopharmaceutical companies. The company specializes in immunology, hematology, and respiratory therapies, providing critical treatments to patients with rare and serious diseases. CSL's portfolio includes well-known brands such as Privigen, Hizentra, and Afstyla, which are vital for patients requiring immunoglobulin therapy. As of 2023, CSL continues to innovate with a strong emphasis on research and development, allocating around 10% of its revenue to R&D efforts, ensuring a robust pipeline of new therapies aimed at addressing unmet medical needs.
Key Financial and Industry Highlights
In recent years, CSL has demonstrated solid financial performance, reporting substantial revenue growth driven by increased demand for its plasma-derived therapies. For the fiscal year ending June 2023, CSL recorded revenue of AUD 10.5 billion, marking a 12% increase compared to the previous year. The company's market capitalization exceeds AUD 80 billion, reflecting its significant influence in the biotechnology sector. CSL's commitment to sustainability and social responsibility further enhances its brand reputation, as the company actively participates in initiatives aimed at improving patient access to life-saving treatments globally. With a consistent focus on innovation, operational excellence, and strategic acquisitions, CSL Limited is well-positioned for continued growth, reinforcing its status as a leader in the global biotechnology landscape.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
